BRCC3 Inhibition Combined with NAD+ Boosters Reverses NLRP3-Driven Immunosenescence in Aging Humans

Hypothesis

Combined pharmacological inhibition of BRCC3 deubiquitinase and augmentation of mitochondrial NAD+ pools will break the NLRP3‑driven feed‑forward loop, reduce SASP, and restore youthful hematopoietic composition in older adults.

Rationale

NLRP3 activation depends on BRCC3‑mediated deubiquitination, a step that thiolutin can block[https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1624770/full]. Simultaneously, NAD+ depletion compromises SIRT3 activity, leading to acetylated mitochondrial proteins, increased ROS, and mtDNA release that fuels NLRP3[https://pmc.ncbi.nlm.nih.gov/articles/PMC12517589/]. NAD+ precursors such as nicotinamide riboside replenish the pool and enhance mitophagy[https://pmc.ncbi.nlm.nih.gov/articles/PMC12711513/]. We propose that hitting both nodes will produce a synergistic suppression of inflammasome signaling beyond what either agent achieves alone.

Mechanistic Insight

BRCC3 inhibition prevents NLRP3 oligomerization, lowering caspase‑1 cleavage and IL‑1β/IL‑18 release. NAD+ restoration activates SIRT3, which deacetylates SOD2 and improves antioxidant defenses, decreasing mitochondrial ROS. Reduced ROS diminishes mtDNA oxidation, removing a key NLRP3 trigger. The dual attack therefore interrupts the cycle where inflammasome‑derived cytokines further damage mitochondria via gasdermin‑D pores.

Experimental Design

• Population: 60‑80 year old individuals with elevated plasma IL‑6 (>2 pg/mL) and a CD4+ naïve T‑cell fraction <40% (n=120).
• Arms (randomized, double‑blind, placebo‑controlled):
  1. Placebo
  2. Thiolutin oral low dose (based on preclinical safety) daily
  3. Nicotinamide riboside 500 mg twice daily
  4. Thiolutin + nicotinamide riboside (same doses)
• Duration: 12 weeks
• Primary endpoints:
  • Change in plasma IL‑1β and IL‑18 (ELISA)
  • Shift in hematopoietic stem‑cell bias measured by CD34+ CD38‑ lineage output (flow cytometry)
  • Naïve versus memory CD4+/CD8+ T‑cell ratios
• Secondary endpoints:
  • Mitochondrial ROS in peripheral blood mononuclear cells (MitoSOX)
  • SIRT3 activity assay
  • SASP cytokine panel (IL‑6, TNF‑α, MCP‑1)
  • Physical function (6‑minute walk test)
• Statistical plan: ANOVA with post‑hoc Tukey; power 0.8 to detect 20% change in IL‑1β.

Expected Outcomes

If the hypothesis is correct, the combination arm will show:

• ≥30% reduction in IL‑1β/IL‑18 versus placebo
• ≥25% increase in naïve T‑cell fraction
• Normalization of CD34+ lineage output toward lymphoid markers These changes will be significantly greater than either monotherapy, indicating synergy. Failure to observe added benefit would falsify the synergistic claim.

Potential Pitfalls and Mitigations

• Thiolutin may have off‑target effects; we will monitor liver enzymes and include a safety run‑in.
• NAD+ supplementation efficacy varies with baseline levels; we stratify randomization by NAD+ metabolite levels.
• Long‑term inflammasome inhibition could impair host defense; we limit exposure to 12 weeks and track infection rates.